Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science

Executive Summary

• Doseology Sciences Inc. began pilot production of non‑nicotine, caffeine‑based “Feed That Brain” energy pouches in late January 2026, marking its first entry into pouch‑based stimulant delivery.
• The pilot products contain no nicotine and are intended for a limited direct‑to‑consumer rollout to gather consumer feedback and operational insights before any broader commercialization.
• The initiative builds on Doseology’s December 2024 acquisition of the Feed That Brain brand for $400,000 (settled via securities issuance) and follows the appointment of strategic advisor Joseph Mimran under a three‑year, $400,000 restricted‑share agreement.

Key Details

• Pilot Production Launch – Small‑scale manufacturing of caffeine‑pouch format started in late January 2026; product is marketed under the “Feed That Brain” brand.
• Product Characteristics – No nicotine; delivers measured caffeine dose in a discreet, non‑liquid pouch; avoids sugar, carbonation, and large‑volume consumption.
• Commercialization Plan – Limited direct‑to‑consumer sales expected within weeks to collect feedback on taste, efficacy, and user experience; data will inform future scale‑up decisions.
• Acquisition Background – Doseology acquired Feed That Brain in Dec 2024 for $400k via issuance of securities; the brand previously focused on functional gummies and nootropic formulations.
• Strategic Advisor Appointment – Joseph Mimran engaged as Strategic Advisor (3‑year term, $400k in restricted share units) to support product development and regulatory compliance.
• Leadership Comments – Tim Corkum, President & COO, emphasized a “disciplined and intentional approach” to evaluating new formats; highlighted the brand’s strong functional‑product design foundation.
• Market Context – Functional beverage market projected to reach $179.26 bn in 2026; caffeine pouch format positioned as an alternative to sugary energy drinks amid growing consumer demand for clean‑label, portion‑controlled products.
• Company Footprint – Doseology maintains a national Canadian presence with functional mushroom tinctures (500+ retail locations) and operates a U.S. subsidiary developing combined caffeine/nootropic/adaptogen pouch offerings.

Notable Quotes

“This pilot reflects a disciplined and intentional approach to evaluating new product formats within our platform,” — Tim Corkum, President & COO, Doseology Sciences.

Materiality Assessment: Non‑Material – Positive (pilot launch provides positive operational insight but does not yet constitute a material financial event).